Acepodia Plays Dual-Payload Ace To Join Global ADC Race

 
• By Dexter Jie Yan

Acepodia’s dual-payload antibody-drug conjugates can link multiple tumor-killing agents without antibody modification. Apart from a GPC3-targeting candidate, the Taiwan-US biotech is also working on a bispecific antibody ADC with two different payloads, its CEO tells Scrip in an interview.

Two,Darts
Acepodia's dual-payload design is believed likely to overcome malignant tumors’ resistance to single-payload ADCs and thus improve survival benefits including overall survival. (Shutterstock)

More from Interviews

More from Leadership